Enlivex adjourns AGM; reconvenes Nov 17, 2025; deadlines set

Enlivex Therapeutics Ltd. reported that its 2025 Annual General Meeting of Shareholders was convened but adjourned due to a lack of quorum.

Rhea-AI Filing Summary

Enlivex Therapeutics Ltd. reported that its 2025 Annual General Meeting of Shareholders was convened but adjourned due to a lack of quorum. The meeting will reconvene on November 17, 2025 at 7:00 p.m. Israel time at the company’s offices in Nes Ziona, Israel.

Voting deadlines were extended: mailed proxies are due by November 14, 2025 at 7:00 p.m. Israel time, and telephone or internet voting is open until November 13, 2025 at 11:59 p.m. Eastern time. Shareholders holding through the Tel Aviv Stock Exchange may vote in person with an Ownership Certificate, by proxy with an Ownership Certificate delivered by November 13, 2025 at 7:00 p.m. Israel time, or electronically via the Israel Securities Authority system until 1:00 p.m. Israel time on November 17, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ENLV announce about its 2025 Annual General Meeting?

The meeting was convened but adjourned for lack of quorum and will reconvene on November 17, 2025 at 7:00 p.m. Israel time at the company’s offices.

What are the new mailed proxy deadlines for ENLV shareholders?

Mailed proxies must be received by November 14, 2025 at 7:00 p.m. Israel time.

When does telephone or internet voting close for ENLV?

Telephone and internet voting close on November 13, 2025 at 11:59 p.m. Eastern time.

How can TASE-held ENLV shares be voted?

TASE holders may vote in person with an Ownership Certificate, by proxy with a valid Ownership Certificate delivered by November 13, 2025 at 7:00 p.m. Israel time, or electronically via the Israel Securities Authority until 1:00 p.m. Israel time on November 17, 2025.

Where will ENLV’s reconvened AGM take place?

At 14 Einstein Street, Nes Ziona, Israel 7403618, on November 17, 2025 at 7:00 p.m. Israel time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/10/2025 - 04:30 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: November 2025

Commission file number: 001-36578

ENLIVEX THERAPEUTICS LTD.

(Translation of registrant’s name into English)

14 Einstein Street, Nes Ziona, Israel 7403618

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒        Form 40-F ☐

Annual General Meeting of Shareholders

On November 10, 2025, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), convened its 2025 Annual General Meeting of Shareholders (the “Annual Meeting”); however, due to the lack of a quorum, the Annual Meeting was adjourned for one week to the same time and place. Accordingly, the Annual Meeting will be reconvened on Monday, November 17, 2025, beginning at 7:00 p.m. Israel time, at the offices of the Company located at 14 Einstein Street, Nes Ziona, Israel 7403618. The voting deadline for receipt by the Company or the Company’s transfer agent of a mailed proxy has been extended to November 14, 2025 by 7:00 p.m. Israel time and the deadline for the Company’s shareholders to vote by telephone or internet has been extended to November 13, 2025 by 11:59 p.m. eastern time. Shareholders that hold the Company’s ordinary shares through a member of the Tel Aviv Stock Exchange (“TASE”) may vote their shares as follows (i) in person at the Annual Meeting, by presenting a certificate signed by a TASE member that complies with the Israel Companies Regulations (Proof of Ownership of Shares for Voting at General Meetings), 5760-2000 (an “Ownership Certificate”), confirming ownership of the shares on the record date; or (ii) by proxy, by delivering a duly executed proxy card, together with a valid Ownership Certificate as of the record date, to the Company’s offices at 14 Einstein Street, Nes Ziona, Israel 7403618, Attention: Chief Financial Officer, no later than 7:00 p.m. (Israel time) on November 13, 2025; (iii) electronically, via the electronic voting system of the Israel Securities Authority, up to six hours before the time of the adjourned meeting (i.e., by no later than 1:00 p.m. Israel time on November 17, 2025).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Enlivex Therapeutics Ltd.
	(Registrant)
	By:	/s/ Oren Hershkovitz
	Name:	Oren Hershkovitz
	Title:	Chief Executive Officer

Date: November 10, 2025

2